Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

Duchenne Muscular Dystrophy Clinical Trial

Official title:

PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01126697
• Other study ID #: PITT0908
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: February 2010
• Est. completion date: December 2017

Study information

• Verified date: June 2018
• Source: Cooperative International Neuromuscular Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will include 120 participants aged 8 and up with Duchenne, Becker, or autosomal recessive limb-girdle (specifically: LGMD 2C-2F and 2I) muscular dystrophies that have no clinical cardiac symptoms. Participants will be randomized to one of four arms: Arm 1 CoQ10 alone, Arm 2 Lisinopril alone, Arm 3 CoQ10 and Lisinopril or Arm 4 No study medication. Randomization will be stratified by ambulatory status and corticosteroid use. The primary outcome for the study is the myocardial performance index (MPI), measured by standard Doppler echocardiography. The study will last 24 months with visits at Months 0.5,1.5, 6, 12, 18 and 24.

Following completion of the Clinical Trial of Coenzyme Q10 and Lisinopril, participants will be offered participation in a companion protocol: PITT1215 A Natural History Companion Study to PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies. The objective of this study is to evaluate the longitudinal natural history of DMD, BMD, and LGMD2I and to evaluate the effects of Coenzyme Q10 and/or Lisinopril on prevention of cardiac dysfunction in these disorders.This will be an 18-month longitudinal natural history study designed to accompany the Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years and older

Eligibility

Inclusion Criteria:

• 8 years of age or older

• Confirmed genetic diagnosis of Duchenne, Becker, or Limb Girdle muscular dystrophy

• Beta-blocker naïve

• Screening Doppler echocardiographic MPI measurement greater than or equal to 0.40 for the highest MPI value (spectral and tissue) or circumferential strain measured by STE that is less negative than or equal to - 23

• Normal left ventricular fractional shortening (=28%) and no clinical cardiac symptoms

• Has not participated in other therapeutic research protocol within the last 6 months prior to screening

• Ability to swallow tablets

Exclusion Criteria:

• Spine curvature greater than 30% (based on the x-ray performed at screening)

• History of significant concomitant illness or significant impairment of renal or hepatic function

• History of hypersensitivity to ACE inhibitors

• History of idiopathic or hereditary angioedema or a history of angioedema with prior ACE inhibitor use

• Use of carnitine, creatine, glutamine, or any herbal medicines (this would not include herbal teas unless they are consumed daily with intended medicinal effect) in the 3-months prior to enrollment

• CoQ10 and/or ACE inhibitor use for a duration greater than 6 months

• CoQ10 and/or ACE inhibitor use in the 3-months prior to enrollment

• CoQ10 serum level of 2.5 ug/ml or higher

• Investigator assessment of inability to comply with protocol

Related Conditions & MeSH terms

• Becker Muscular Dystrophy
• Duchenne Muscular Dystrophy
• Limb Girdle Muscular Dystrophy
• Muscular Dystrophies
• Muscular Dystrophy, Duchenne

Intervention

Drug:
• Coenzyme Q10 and Lisinopril
Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Locations

Country	Name	City	State
Canada	Alberta Children's Hospital	Calgary	Alberta
Japan	National Center of Neurology and Psychiatry	Tokyo
United States	Carolinas Medical Center	Charlotte	North Carolina
United States	Lurie Children's Hospital	Chicago	Illinois
United States	University of Tennessee	Memphis	Tennessee
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Cooperative International Neuromuscular Research Group	United States Department of Defense

Countries where clinical trial is conducted

United States,  Canada,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	myocardial performance index (MPI)	The MPI is a sensitive, quantifiable, noninvasive measure of global ventricular function that is independent of cardiac geometry and heart rate. MPI is collected through standard echocardiogram assessment. MPI is a ratio of the total time spent in isovolumic activity (isovolumic contraction time and isovolumic relaxation time) to the time spent in ventricular ejection.	every 6 months

External Links

•   CINRG Network Website